UHS Universal Health Services, Inc.
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; capital resources; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Universal Health Services (NYSE: UHS)
›
Universal Health Services (NYSE: UHS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 102,000 employees.
The shares were at 179.43 USD on 20 November 2026, down 21.5% over 52 weeks. Its 52-week range is 140.08 USD to 246.33 USD: the price is 27.2% below the high and 28.1% above the low.
At a market capitalisation of 10.34B USD, it trades at 7.5 times trailing earnings and 7.8 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, a discount of 68% for UHS. It pays a dividend yielding 0.46% (it pays out 3% of its earnings), against a median of 0.84% among the dividend payers in that peer group.
Universal Health Services reports return on equity of 20.5%, an operating margin of 10.9% and revenue up 5.3% year over year.
Its debt exceeds its cash by 6.01B USD, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 196.71 USD is 9.6% above the current price. The next earnings report is expected on 24 February 2027.